Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ravindraprasad Shekarappa

Internal Medicine Warner Robins, GA Medical Doctor

NPI 1588606701 CMS profile 162601

623 S Houston Lake Rd, Suite 500, Warner Robins, GA 31088

Open in the dashboard

General payments

$12,604

728 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ravindraprasad Shekarappa of Warner Robins, GA is reported in the CMS Open Payments database as having received $12,604 across 728 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,658 98
2024 General $1,687 87
2023 General $2,108 105
2022 General $1,876 103
2021 General $1,907 111
2020 General $1,665 113
2019 General $1,702 111

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ravindraprasad Shekarappa
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ravindraprasad Shekarappa were reported at $1,658. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ravindraprasad Shekarappa Internal Medicine median Middle half National median
2019 $1,702 $159 $48–$570 $163
2020 $1,665 $119 $33–$402 $114
2021 $1,907 $135 $37–$521 $132
2022 $1,876 $141 $42–$496 $149
2023 $2,108 $149 $45–$519 $160
2024 $1,687 $154 $47–$537 $164
2025 $1,658 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,506 88 payments
  2. AstraZeneca Pharmaceuticals LP $1,287 77 payments
  3. GlaxoSmithKline, LLC. $967 53 payments
  4. Janssen Pharmaceuticals, Inc $944 66 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $866 44 payments
  6. Pfizer Inc. $795 46 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $700 43 payments
  8. Amgen Inc. $623 48 payments
  9. Lilly USA, LLC $595 42 payments
  10. AbbVie, Inc. $552 26 payments
  11. Other $3,770 195 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,105 720 payments
  2. Debt forgiveness $267 2 payments
  3. Education $232 6 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,023 58 payments
  2. FARXIGA $1,022 61 payments
  3. XARELTO $938 65 payments
  4. Kerendia $866 44 payments
  5. RYBELSUS $843 46 payments
  6. TRELEGY ELLIPTA $820 45 payments
  7. ELIQUIS $500 31 payments
  8. Otezla $500 41 payments
  9. NURTEC ODT $484 25 payments
  10. JARDIANCE $418 28 payments
  11. Other $9,408 565 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 204 drugs

Part D claims

18,406

Median for Internal Medicine: 777

Drug cost

$1,727,731

Median for Internal Medicine: $73,373

Branded share of claims

20%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 287 $224,471
Ozempic Semaglutide Brand 146 $182,590
Farxiga Dapagliflozin Propanediol Brand 180 $179,509
Mounjaro Tirzepatide Brand 128 $145,694
Trulicity Dulaglutide Brand 58 $92,281
Januvia Sitagliptin Phosphate Brand 93 $84,182
Jardiance Empagliflozin Brand 65 $83,691
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 56 $61,966
Xarelto Rivaroxaban Brand 90 $61,293
Kerendia Finerenone Brand 47 $49,803

The 10 drugs with the highest cost, of 204 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$282,179

Of which drugs: $1,233

Medicare patients

1,233

Average age 76

Services billed

4,346

696 women, 537 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 54%
Arthritis 53%
Diabetes 49%
Ischemic heart disease 38%
Heart failure 31%
Depression 29%
Atrial fibrillation 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 36 64 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $232
$232 47 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $120
$120 180 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $96
$96 56 —
AREXVY
  • GlaxoSmithKline, LLC. $96
$96 16 —
Ozempic
  • Novo Nordisk Inc $89
$89 146 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

728 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record